and by url pharma, using smarter science to deliver safer medicines.nd by novartis vaccines, a leader in providing products to fight preventable viral and bacterial diseases. and by sanofi, a diversified global health care leader. discovers, develops, and distributes therapeutic solutions focused on patients' needs. we work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. additional funding provided by: vertex pharmaceuticals. and by biogen idec. >> mcfarland: welcoming a new baby into the world can be a precious and beautiful time for many families. but if the delivery comes too early in the pregnancy, that special moment can begin a physically and emotionally challenging journey for both the parents and the child. >> go, baby. come on, push, sweetie. >> mcfarland: babies delivered after 37 weeks are considered full-term. a full-term pregnancy provides the best opportunity for a mother to deliver a healthy baby. >> well, it's important that a woman achieve term, or deliver at least at 37 weeks of gestatio

the insurers, hospitals, pharma and diagnoses won't see the bump in business. the hardest hit could be the insurers in the medicaid space. they're the ones expected to gain the most from that new big pool that starts in 2014. so far this year, diagnostics, device makers, insurers have all seen double-digit gains. but the overall health care sector has lagged the market, dragged down by pharma. the court will hear the argument in a couple of weeks. but it's being said that's likely to keep investors cautious on health care until the actual decision which isn't expected until june. it could be a rocky road over the next couple of months for health care. coming up on the "closing bell," the court could choose a compromise option. why some analysts say that could be the worst-case scenario. >> as bertha laid out, seems as though the medical device makers have the most at stake on the outcome of the supreme court ruling on obamacare. some stocks in the sectors are off the charts. joining us with his favorite picks to own is les funtlier. you have a number of picks i

trying to figure out new ways to bring in knowledge transfers, so i think a key theme is for big pharmapanies trying to figure out how to market their products in china, you have got to figure out how you will share knowledge and economics with local disvibes by the and think there is interesting things they can be doing and thinking about doing they look to tap into that growth market. >> we have certainly seep a fair amount of deal flow happening in health care, how does the m and a action look to you, what do you expect for 2012, the m and a side of things or financing? >> seep a tremendous amount of activity. i think the big theme this year is competition from big biotech and emerging farm ma. we have seen things happen this year in particular where some of the biotech companies, the larger biotech companies are acquiring smaller biotech companies and the giving pharma competition. we have seep people interested in acquiring platform technology also, oncology, hepatitis c and key themes driving biotech valuation. on the financing side, listen, with the nbi up 15% the first two month

takes effect with hungry getting its funding slashed or something is given to spain and the region's pharma say the other words forcing them to send us a red tape. next to the stock of the grocery covered by digging deep in the rubbish bins. every year in america we throw away ninety six billion pounds and lose. two hundred sixty three million pounds a day. eleven million pounds an hour. three thousand pounds a second. the be . the end. of. the beyond. players. who mom. played. the bombs nearly a billion people in the world are going hungry every day. in the united states even our trash cans are filled with food you just have to go get it. so there are three basic rules to dumpster dive rule number one never take more than you. unless you find it if your rule number two first ones to the dumpster as first did. that you always gotta share and rule number three leave it cleaner than you look and you. found it before you leave it cleaner and you found some right it's an unusual night in l.a. because it's it's freezing outside freezing for l.a. so i think it's you know forty three to forty five

the the the socialists the marxists the internationalist they did warmly supporters and that was pharma radicalism the grange movement another tact but communism what they call the communism of combined wealth they would very much against the large railroad companies for example which would go and take over the land and would charge high prices to the farmers to transmit their produce to market so there was quite a lot of intense cost profit in in that whole second half of the nineteenth century here in the united states and you could say some of marx's ideas they definitely fell on fertile soil and you got the founding of the air fell for example you have merican federation of labor now samuel gompers the leader of that. claim to be a very moderate man but i actually he read capital he read marxist great work capital and he certainly learned from it and it helped to inspire his organizing activities and it's only later he became rather moderate robert i'd like to dig a lot deeper into this into the whole concept of marxian economics and the difference between march in thinking in marxi

concern its national concerns have been causing the sponsor a slate but right now putting severe pharma administration there saying that i do refineries in the u.s. could really affect. the shortages and the therefore the prices of course that's a concern at the moment if you look out the us a finished up yesterday because it was a disappointing day after all it was disappointed so it was very good indeed actually to do that now because of course going to talk about apple that was a top story yesterday people still excited about it i can also tell you that ten year treasuries also extended their longest slumps is two thousand and six and that's because sensibility in the u.s. economy is strengthening so to clarify it's a good day yesterday let's get on to the current says we can see the euro is now losing against the dollar that we've got mixed sentiment from the ruble which is now open for business now gold is an interesting stock for today precious metals are under pressure themselves and this is a strike by jewelers in india india is the biggest consumer of gold we know that i love i

the pharma world does it a lot. the pharmaceutical world might want you to take interest in a bladder disorder. that might be an unbranded ad and what they could say about bladder disorder and that might be followed by a branded advertisement for their bladder solution having paved the way. there's an analog in our commercial world for branded and unbranded. in terms of attack i don't know that i think there's a perfect analog but certainly in the southwest example and many those we will take on a myth call company or theoretical company and it's lost on who we are attacking. those are the two analogs for me. >> i think there's a sensitivity that people feel in corporations. for example, our walmart client is sensitive to the fact that they can't be out there saying we're doing the sustainability thing. what they have -- what their customers say, customers say, look, wul 200 million walmart shopper it is we all do this, it will make a difference. the customers get credit for it. because a big company like walmart ha

it is fine for big pharma and big insurance. that is why big pharma has spent $150 million lobbying for the bill. they showed up for the white house. billy tauzin had met with the president he came out with all sorts of agreements to spend money and campaign for the bill because they know a lot of the bill were ever insurance has to cover prescription drugs at the lot of new expansions and medicare for them and they are going to have brand-name drugs covered under the doughnut hole where they were going to generics. so they came out ahead. big insurance dropped the public option is to $70 billion a year. the small medium insurance companies can comply they will go out of business, but that is great for insurance companies who will control the market. i think the ama lobbied in favor of this bill because they think that is going to mean that their dog or is there going get special treatment under this. they look at the doc put him in things like that. so i think this is a great tool for big business. i think it is just the little

combination of both things it's hard to talk about farmland to generally because in some parts of the world pharma is expensive and some parts of the cheaper u.s. farmland example i don't think is a particularly good investment right now the western canadian farmland is cheap relative to the provinces around it and she compared to the u.s. and that's two fold like you say some of it is it's going to be because currency has been debased as a real tangible asset hold its value and part of it is because we have this global shift and many millions of more people joining the middle class and spending more of their income on things like meat and fruits and vegetables which are much more green intensive and so we see a lot of that. but we're running out of it because i want to bring up another try to show how the supply has declined per person of arable land over the years over the decades really how much of this is supply versus demand with some good balance is another good point man is. we've done a lot more with an acre of our my now than we could do forty years ago but you look at some of those games

they are playing the future for at least the pharma industry. >> in terms of the handicapping, are youat indicate any guesses? >> we are seeing bullish blows in well point and unitedhealth. that's consistent with the view and pfizer traded over three times the daily volume based on the same things they were just talking about. >> an issue we will continue to watch. next on fast hot topic, a lot riding on the "hunger games" success. what happens at the trade if it falls apart? that's up next to answer your questions. # >> >>>> you sent the guys an e-mail to congratulate them. it's impossible to pick the right movie. >>> that was carl talking to maria about why he sold out of lions gate shares is prior to the huge run that they have seen on the "hunger games." not a good trade as carl mentioned. he was sending those guys an e-mail and overall his performance has been good, but the lions gate story is unbelievable. >> yeah. we saw him today. he was here and the funds are up 34%. he's having a great year. we thought he had it wrong from the get go and we were on his side. that turned out t

it's a bio pharma company focused on a late-stage product called levidex.ts acute migraines in adults. you may have heard us mention this company on the show, before. in relation to allergan, which collaborated with a company that works on neurologists for its botox migraine. this is a bionary trade. the fork has been very volatile and will likely trade up or down sharply on the news. if you are a risk-associated trader, then go with this. if you are less of a risktaker, go with allergan. and fred asked me about oxford industries, oxm. this near $800 million market the company is an international apparel designed company. including tommy bahama, lily pulitzer and len sherman. they have invested in the manufacturing piece of their business and acquired lily pulitzer. so now oxm is a retail/life-style brand versus a vendor. all of the oxford brands are growth brands. ben sherman, a turn around to boot. it has traded above value nation 15 times. and it could be underestimated, given the transition. drive growth and dry drive a higher multiple. an overlooked na

switching over to pharma, two big movers. moving higher it's said to be buying swiss based actavis. it brought in $1.2 billion in sales last year. big news there. on the flipside, we have shares dripping after the supreme court throughout two of the competitors' testing medical pens. the fear is that the patent could be thrown out as well. ruby tuesday getting a boost after raymond james upgraded the stock to outperform. that stock up better than 11%. maria? >> seema, thanks so much. we're gaining ground today after the disappointing data on existing home sales and the fed's purchase of $4 billion in u.s. debt. rick, we were all waiting, all this housing data this week hasn't been very impressive. >> no. and you know we expect that we're going to be bumping along in what at least looks like a temporary or long-term bottom. with all of the good weather, it's hard to discern what may lie ahead because we might have pulled it forward. even though existing home sales might have disappointed some, others say it came close to expectation and the rally in treasuries, in boons really was un

pharma in first. that manage over $1.6 billion. a pleasure to speak to you again.ommon theme. >> we look at the drugs and the patent cliffs are on the branded side and if you look at the expectations, generics grow at 7.4% compounded over five years. so there good companies with high returns and that's what we like. the first one is mylan. some come from generics and we also have watson. roughly 3/4 is generic and 1/4 is branded. that's growing at double-digits and then the biggest give away is te va. 56% of the company is generic and 44% branded. they have taxes and this stock is a joke. they generate over three billion a year and 20% and 7.8 times this year's earnings. ludicrous. >> they're had the piece that 91% is from generics. does the volatility, this is a stock that moves. is that scary? it's not one of the slow and steady up rising types of stocks. this thing moves. >> we don't look at volatility. we call the company several times and they state an objective for roughly 8 to 10% top line growth. between 15 to 20% from a combination of margin improvement an

his planter will sew six rows at a time but his pharma sheens are in mothballs and his fields lie fallow. he and his wife are back home-- alone-- in a village about 13 miles from the fukushima daiichi nuclear power plant. the village is not officially in the mandatory evacuation zone but it is contaminated with cesium fallout and the farmers were told not to plant their rice fields so the place is all but abandoned. "i was born and grew up here" he told me. "but this land and these houses are inherited for generations, we have to protect them so we can't help but return." but it's not easy living here now. the family drives more than an hour just to stock the fridge. and everywhere they turn, they are reminded of happier times. when they measured their children's height on this door frame. so this is... they showed me pictures of them and the grandchildren-- all gone now because they don't believe it's safe to live here anymore for fear of radiation contamination, in the air and in the food. in food, radiati contamination is commonly measured in a unit known as beck rells. the government

we have other avenues we're funding, other areas that we're supporting, and we work a lot with pharmasearch they're doing and we'll give like $5 million grants to local companies to so they will work on compounds of interest to us. give like loans or grants to because the pipeline is so time consuming that we want to keep it moving. we'll continue to do that, but again, if you have people that based on idealogical reasoning can just make summary decisions about what you can pursue, i mean, it would really be dangerous for us. >> i asked you about your day-to-day work. as you're sitting here, are you struggling? are you aware of trying to keep your movements in check? i want to get inside you because we know you and i know you personally and you're a dear friend and such a special guy. is this a fight for you every second or you're talking like i'm talking. >> i'm talking like you're talking and i'm aware i'm moving. and i strive for comfort and ease as much as i can more than vanity and appearance. i -- it's given that i'm going to look like what i look like, and again, that goes to t

we are quite interested in the big pharma names that have good exposure to emerging markets, long-term demand trends and so forth. it's definitely not a political play. >> we'll have you back soon. jeff palma from ubs. >> you can't play the middle of the fence. that's a problem in the marketplace. too many people are saying, yes, the market appreciated. but a correction is coming. draw a line in the stand. you have to be in the market. the treasury yield is 203 thursday up to 231. that's telling you something. you have to be involved. tbt i'm long. look at names that haven't been working lately. they will work again. bought some potash today, joy global if you believe in the mining trade. great place to be. you have to draw a line in the sand. volatile till cheap enough. you can buy the protection. be there. you have to do something. >> there was a look at the tbt. >>> let's talk about our next trade. despite failing a stress test spiking on the week. is there still room for financials to run or time to take profits? dr. j? do you like the group? >> love it. pete has been all over it o

risk and put the risk trade back on probably since mid-january and seeing a bit of a rotation out of pharmarmeded the s & p, utilities, very strong last year, down 2 1/2, 3% a year, a greater appetite for risk, hearing talk about inflation again, leading people to want to buy equities and more a greater conviction that european greece crisis is on the sidelines for now and you focus more on the u.s. recovery, china growth and some other things that are more easily handicapped. >> george, you have seen your share of bull and bear markets, when do we start to enter a complacency period? are we there yet, do you think? >> the markets very placid for the last several months and responding to the same cues, as dan said, recent pore chu gal, iran in oil, it has been u.s. growth in china not growing quite as well. the longer a market extends a tranquil period, generally, the greater the eruption, up or down. sort of like a forest fire. >> are we there yet? >> i think we are on the brink of it, a new set of chew drive the market, the market is tight hearten old ones and one or two that are thought

analysts over at goldman sachs laying out potential scenarios for pharma giant, pfizer, that could unlock shareholder value. shares of pfizer are up more than 2% today. what's notable about that move, pete, the stock basically hasn't done anything for the year, thus far, after being one of the best performers in the dow last year. what do you think about this? their note, i'm quoting from it, to give you insight here of what the thought is at goldman sachs. they recently met with the ceo who expressed an openness to going further with separations beyond animal health and nutrition if the conditions make sense. you've owned this a long time. >> long time. multiple years. an eternity. people are starting to get a little more attraction to is the idea, look at abott, they announced something similar, split off into division. 52 week high, 52 week high. unlock that value. this is a company, stooeeve and were talking about it in the break, this pharmaceutical area has performed nice. look at the xlv. people have gone for areas where they find valuations and getting great dividend yields. that'

it will be the big pharma companies but companies like biomarker in and shire, genzyme, they are into that stuff. identifying tricks. the only problem your bring up, it's not a matter of coming up with nature, it's coming up with a palatable price, okay? because the price of these drugs are outrageous. and like, for example, that kalydeco drug for cystic fibrosis, that cost $240,000 a year. it comes the molecular trams of the disease of cracking the disease. that's the problem. just? >> a lot of the apps that are out there like my heart rate and all that other kind of stuff, there's a lot of great ones coming as you point out. the interesting thing that i'm unclear about is okay, so you get, so even if you get all this great data, aren't you going to end up having to go back to the same position who really don't want to hear, don't want you to be educated, aren't all that familiar with the stuff to begin with? i mean, there's a cycle here, and i think you are advocating facebook and that kind of thing but i'm not sure, how do we break that apart? what's happening from the outside? >>

it's one of the holy grails if you will, for pharma and biotech.l is going to hold a critical vote on fat-fighting drugs today. we'll tell you what it means to key stocks like vivus. >>> plus, investing in america, costco hitting its best level since the company's 1985 ipo of more than 900% in the past 20 years. is it still a buy? stick around and find out. this is $100,000. we asked total strangers to watch it for us. thank you so much, i appreciate it, i'll be right back. they didn't take a dime. how much in fees does your bank take to watch your money ? if your bank takes more money than a stranger, you need an ally. ally bank. no nonsense. just people sense. (sfx: car garage sounds) today my journey brings me to charlotte, north carolina, where i spent the day with geico driver casey mears. i told him the secret to saving money on car insurance. he told me the secret to his car setup. first he adjusts... first he adjusts... (sfx:engine revving drowns out gecko's dialogue) then he... then he... (sfx:loud drilling noise continues to drown out gec

wattson pharma reports close to buying for close to $7 million. up for a second straight day. this could be a transformative deal if they do close. lastly, a look at tivo, dismissing patent litigation with microsoft. the market always liking clarity. that stock up better than 1%. tyler, back to you. >> seema, thank you very much. the dow and s&p on track now for their worst weekly declines of the year so far. renewed worries on the eurozone and a slowdown in china overpowering positive news that u.s. jobless claims hit a four-year low. now, after a bull run over the past few months, have investors missed their opportunity to jump in just a day after goldman sachs says it's the best opportunity of a lifetime? joining us is chief investment strategist with raymond james. and destination wealth management ceo and a cnbc contributor. so which is it, jeff? the best time in a generation to get? or a time when the best moment has passed? >> i don't know if it's the best time in a generation. i do think that stock valuations are still pretty inexpensive for the past few weeks i have b

we'd be neutral on big pharma. certainly areas are leveraged to economic success or pricing pressures that we'd be underweight. >> how do you feel about the bond trade that everybody's hot on at this point in. >> it's a really interesting thing. one of the ways that we value equities based on our mod is also this relationship between high-yield stocks -- high-yield bonds and stocks. right now the high-yield market is actually more frothy than the equity market, which is one of the reasons why we think that multiples on stocks will tend to move up a little bit. so it's a good question. >> what is your view on -- bob pisani just pointed out that the global growth slowdown, if you can call it that, is affecting today industrials and materials. do you have any views on that? >> yeah, take a look -- one of the sectors that are most sensitive to european macro concerns and economic weakness, it's the banks, materials, energy and the fourth one is industrials. we like technology and the american consumer which is still ho

the front of the store did fairly decentury but the pharma sales was bad. whether or not that continues or not it's interesting to hear on the conference call and filling that hole once again. with other deals. >> only so long to say -- this is operating earnings. going forward, you can't asterisk it. if this is 150-game season, not 163 -- what you are looking at here is a company that's made a bad point and the stock is up today. i think that's warm and fuzzy for walgreen's. it's the future. you're right. all the questions about xspress scripts. >> all right. the just released case-shiller home price report cards. also, building your portfolio by investing in america, the kramer way. looking at futures, follow through on yesterday. more live from post 9 in just a moment. the most spectacular experiences are happening here. imax now showing on the big board. introducing gold choice. the freedom you can only get from hertz to keep the car you reserved or simply choose another. and it's free. ya know, for whoever you are that day. it's just another way you'll

impacted with cancer medication -- dispensed instead of fluoride pills by a cb in the new jersey a cvs pharmaarch until april impacting 1300 workers. the only sold 1000 of the chevy volts much below their anticipated total. >> 8:42 her. >>jan: john wilkes booth is obsessed, weird and it is an of row involving president lincoln and opera -- ♪ ♪ tnkle toes i think i found a so ♪ ♪ to make me happily ever after ♪ ♪ i say i love you and i'll say it more ♪ ♪ my one and only ♪ oh i can't lose ♪ so don't stop doing what you do ♪ ♪ don't stodoin what you do ♪ great! at progressive, you c compare rates side by side you get the same coverage, often for less. wow! that is huge! ♪ and this is to remind you at you could save hundreds! [laughing] man: yh. that will certainly stick with me. we'll take it. go, big ney! i mean, go. same coverage, more savings.. callr click today. ♪ opera singing >>jan: 6 ft. 6 in.. he is planning president lincoln. it is an opera. it is obvious what it is about. president lincoln and john wilkes booth. what these men did through history and how they changed the world. please

it won't be the big pharma companies but companies like -- is part -- they are into that stuff. identifying drugs. the only problem is it is not a matter of coming up with the drug but a palatable price. it is outrageous. the drug for cystic fibrosis. you know what that costs? $294,000 a year which is a tragedy. molecular triumphs of the disease is the problem. >> i am aware of all the air one out there like my heart rate and great ones coming. the interesting thing i am unclear about is so you get -- even if you get this great data aren't you going to end up having to go back to the same physicians who don't want to hear it, don't want you to be educated, are not familiar with this stuff so there's a cycle here -- what is happening from that side? >> there's a whole chapter in a book about digital doctors. there are some of them but body of. basically there are places like hello hell where they do a lot of visits through skype, facetime and data sent through sensors. during the visit that is done -- practices of medicine. we get physician based, that is a big part of the proble

clearly this administration and outside of iowa was on that side of pharma, because they got a sweetheart deal of $150 billion that would of been saved if we would of been able to reinforce prescription drugs. a r pete got a sweetheart deal. got a sweetheart deal. there was throughout this, we should have set up a tent and put a person webs in front of it. that is the way this has been conducted pier yen and the the we have to take care of special senators. we have the louisiana purchase, cornhuskers' kickback. i got the florida flim flam, the one get that gives the medicare advantage in florida, but my constituents do not. so an answer to this question today, the majority leader said "a number of states are treated differently than other states." really? legislation is all about. that is compromise. where is that what? a number of states are treated differently than other states. that is what legislation is all about. that is compromise. that is not what the american people call in governing. that is called an opposite definition of what the president of the united states said where he s

agents that administer the programs, they'll pay for it and somehow they'll get the money from big pharmaand they'll kick in dollars and we'll make it all right and women's rights will be preserved and we'll also preserve religious liberty. they're not preserving religious liberty and it's phony about religious rights. >> when they say it's a war on women, you say? >> well, that's a fiction. it's a short-term political war in 2012 to ensure that the president wins. the problem is those who are defeated are those that stand up for religious liberty. this time it happens to be catholicism. catholics that is hurt but in the future, who will it be? what group will be hurt by the lack of religious freedom that's being perpetrated by the federal government, by this obamacare mandate. today, it's the catholics. tomorrow, who knows? >> well, in listening to cardinal dolan, he's not going to -- >> he's not backing down and the catholics are the swing vote in this election. >> you're right. all right, peter johnson jr., thank you very much. >> good to see you. >> straight ahead, he may be down in d

the argument we hear is if we allow the players in the health care industry, including big pharma, manufacturers of medical devices and even big insurance companies and h.m.o.'s who refuse to pay for service, if we allow them to escape from the harm they inflight, we'll all be better off. this is not true and has never been true and despite the extravagant plays of the bill, that will not be true of this multibillion dollar gift if this were to become law. how pricey a gift to industry are we talking about here? according to the congressional budget office, $45.5 billion over the next decade. anyone who believes that those savings will be passed along directly to consumers or to health care providers and victims of medical malpractice is living in a dream world. some of us will remember the debates we had in this house for the eight years preceding enactment in 2009 -- of 2005 of the bankruptcy code rewrite will no doubt reremember the argument that abuse of the bankruptcy system was a hidden tax for every american and tightening the rules would be in the interest of all americans. we passed tha